There are 2867 resources available
707TiP - Postoperative adjuvant radiochemotherapy (aRCH) with cisplatin versus aRCH with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma: The ADRISK trial
Presenter: Susanne Wiegand
Session: Poster session 10
708TiP - BD4QoL: A multicenter randomized trial for monitoring quality of life (QoL) by intelligent tools in head and neck cancer (HNC) survivors after curative treatment
Presenter: Stefano Cavalieri
Session: Poster session 10
891P - Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial
Presenter: Jaume Mora
Session: Poster session 10
892P - Hedgehog (Hh) activation in neuroendocrine neoplasms (NENs)
Presenter: Carmen Blanco Abad
Session: Poster session 10
893P - Autophagy flux is induced in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
Presenter: Ioanna Angelioudaki
Session: Poster session 10
894P - Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia
Presenter: Ludovica Magi
Session: Poster session 10
895P - Correlating peptidylglycine alpha-amidating monooxygenase (PAM) expression with clinicopathologic variables in gastrointestinal (GI) neuroendocrine tumors (NETs)
Presenter: Jordan Sim
Session: Poster session 10
896P - Multiple radiomic biomarkers-based machine learning model to predict responses of surufatinib-treated advanced neuroendocrine tumor (NET): A multicenter exploratory study
Presenter: Jianming Xu
Session: Poster session 10
897P - HORMONET: Phase II trial of tamoxifen for patients (pts) with estrogen/progesterone receptor (ER/PR)-positive neuroendocrine tumors (NET)
Presenter: Rachel Riechelmann
Session: Poster session 10
898P - The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study
Presenter: Jiang Long
Session: Poster session 10